Our findings show that dual therapy with an ACE inhibitor and an ARB had no additional beneficial effect on major cardiovascular and renal outcomes when compared to an ACE inhibitor or ARB alone in adults with diabetes. The gene discussed is ACE; the disease is diabetes mellitus.